Low rates of adverse cutaneous effects seen with successful, appropriate life-saving shocks<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Aug. 2, 2024 (HealthDay News) — A novel, water-resistant patch-wearable cardioverter-defibrillator (P-WCD) is safe and effective for patients at risk for sudden cardiac arrest, according to a study published in the Aug. 6 issue of the\u00a0Journal of the American College of Cardiology<\/em>.<\/p>\n John Hummel, M.D., from The Ohio State University in Columbus, and colleagues assessed the safety and clinical effectiveness of a novel P-WCD. The analysis included 290 patients at risk for sudden cardiac arrest due to ventricular tachycardia\/ventricular fibrillation who were not candidates for or refused an implantable defibrillator.<\/p>\n The researchers found that the clinically significant cutaneous adverse device effect rate was 2.30 percent, with no severe adverse effects. There were no device-related deaths or serious adverse events reported. The inappropriate shock rate was 0.36 per 100 patient-months. Nine patients received 11 shocks, of which nine shocks were adjudicated to be appropriate. Eight of nine appropriate shocks were successful with a single shock. Median wear time compliance was 23.5 hours per day.<\/p>\n “There were no patient deaths or missed episodes requiring external rescue, and high patient compliance enabled a high number of successful life-saving conversions,” the authors write.<\/p>\n Several authors disclosed ties to medical device companies, including Element Science, which manufactures the studied P-WCD and funded the trial.<\/p>\n Abstract\/Full Text<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n